Prognostic utility of lncRNAs (LINC00565 and LINC00641) as molecular markers in glioblastoma multiforme (GBM)

Rehab G. Amer1 · Lobna R. Ezz El Arab1 · Dalia Abd El Ghany1 · Amr S. Saad1 · Nermean Bahie-Eldin1 · Menha Swellam2

Received: 25 February 2022 / Accepted: 5 May 2022 / Published online: 6 June 2022
© The Author(s) 2022

Abstract

Background and aim Glioblastoma multiforme (GBM) is primary brain tumor grade IV characterized by fast cell proliferation, high mortality and morbidity and most lethal gliomas. Molecular approaches underlying its pathogenesis and progression with diagnostic and prognostic value have been an area of interest. Long-non coding RNAs (lncRNAs) aberrantly expressed in GBM have been recently studied. The aim is to investigate the clinical role of lncRNA565 and lncRNA641 in GBM patients.

Patients and methods Blood samples were withdrawn from 35 newly diagnosed GBM cases with 15 healthy individuals, then lncRNA565 and lncRNA641 expression were evaluated using real time-PCR. Their diagnostic efficacy was detected using receiver operating characteristic curve. Progression free survival (PFS) and overall survival (OS) were studied using Kaplan–Meier curves.

Results lncRNAs expressions were increased significantly among GBM as compared to control group. Their expressions were correlated with clinico-pathological data and survival pattern for the studied GBM patients. Higher levels of both lncRNAs were correlated to worse performance status. Expression of lncRNA565 was increased with large tumor size (≥ 5 cm). Survival analysis showed that both investigated lncRNA were increased with worse PFS and OS.

Conclusion Expression of lncRNA565 and lncRNA641 in a liquid biopsy sample can be used as prognostic biomarker for GBM patients.

Keywords lncRNA · Glioblastoma multiforme · Prediction · Prognosis · Response

Introduction

Glioblastoma multiforme (GBM) is the most common, aggressive and poorly prognosed brain tumor that represents about 82% of primary CNS malignancy in adults. It was classified as grade IV tumor by the World Health Organization (WHO) [1]. Previously, it has been reported as an age-related neurological disease [2], among Egyptian adult GBM patients has reported to be of 50 ± 2 years [3–5]. No definitive causing etiology has been found, but factors that may be related to GBM risk are: decreased susceptibility to allergy, immune factors and immune genes, and some nucleotide (nt) polymorphisms [6]. Despite of the progress has been made in the standard treatment as resection techniques, radiation therapy, and chemotherapeutic strategies, the median survival are about 15 months [7]. The WHO classification in 2016 included molecular parameters in the diagnostic schema, as it’s more relevant to outcome than histological grading alone [8]. Recently, the fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS-5)—published in 2021—magnifies the molecular diagnostics role in CNS tumor classification [9]. Survival in GBM patients showed to be affected by individual molecular biomarkers [1]. So, it is important to study the molecular variability of GBMs and its effect on the biological behavior of individual GBMs. This can help to adjust methods for proper diagnosis, prognosis and therapeutic response prediction [10].
Since the biggest obstacles of cancer therapy are still present, such as treatment resistance and early recurrence; the search for novel biomarkers has steadily continued. Recently, certain molecular groups have gained increased attention. Non-coding RNAs (nc-RNAs) is one of these groups, although previously thought to be a transcriptional noise with no apparent function. They have two subtypes according to the length: small nc-RNAs are shorter than 200 nts, while long nc-RNAs (lncRNAs) are at least 200 nts long [11]. Long noncoding RNA are RNAs that lack functional protein coding ability, but they are important as players in the complex genome regulatory network, these transcripts may have prognostic or even therapeutic applications [12].

In carcinogenesis, deregulated lncRNAs can affect both oncogenic and tumor-suppressing pathways [13]. lncRNAs are present in body fluids, including serum, plasma, and urine, that allow tracking of the cancer genome without need of a tissue biopsy especially non accessible sites. A variety of studies demonstrate the role of circulating lncRNAs as biomarkers for cancer detection and prognosis in multiple cancers [14].

Some of dysregulated lncRNAs have been reported to play oncogenic and tumor suppressive roles in cancer development, progression, and metastasis. For example: HOTAIR, PVT1, H19 and MALAT1 showed oncogenic effect, while MEG3 and GAS5 have tumor suppressor effect [15]. Through bioinformatics analysis, it was identified that lncR 641 is significantly down-regulated in bladder cancer tissues, while lncR 641 overexpression suppresses proliferation, migration and invasion of bladder cancer [16]. In addition, it was demonstrated that lncR 641 can function as a tumor suppressor in non-small-cell lung cancer (NSCLC) via a competing endogenous RNAs (ceRNA) network [17]. Whereas it was reported that, lncR 565 promoted the progression of ovarian cancer via upregulating GAS6, which has been confirmed to promote tumor progression [18].

In GBM, controlling lncRNAs are under investigated, several studies aimed to identify lncRNAs that could serve as diagnostic, prognostic or predictive markers and correlated them with tumor progression and survival [10]. As example, CASC2, TSLC1-AS1, and ADAMTS9-AS2 are tumor suppressor lncRNAs, while linc-POU3F3, HOTAIR, and H19 function to promote GBM cell cycle progression [19].

Zhang and his colleagues reported a set of lncRNAs (C20orf166-AS1, lncR 645, LBX2-AS1, lncR 565, lncR 641, and PRRT3-AS1) that have prognostic value for GBM [17]. By lncRNAs bioinformatics analysis using Cancer Genome Atlas (TCGA) and formed a risk scoring model based on these lncRNAs to divide the patients into high and low-risk groups. It showed that the low-risk group had significantly longer OS compared to the high-risk group (16.61 ± 14.22 months vs 9.83 ± 6.17 months, P = 0.000127) [20].

Moreover, another study showed significant prognostic value of six-lncRNA signature (LBX2-AS1, lncR 641, PRRT3-AS1, and lncR 565) and significant association with focal adhesion, extracellular matrix (ECM) receptor interaction, and mitogen-activated protein kinase (MAPK) signaling pathways. These four pathways showed involvement of twelve common genes, including TGFβ1 gene [19].

Using liquid biopsy samples for detection of tumor cells has been widely studied [21, 22], because they are clinically useful as minimally invasive approach for early detection of cancer and may be helpful as follow-up markers since they can be present in detectable concentrations [15]. lncRNAs are among the circulating biomolecules that can be studied in liquid samples. Recent studies were concerned about detection of lncRNAs in blood samples from solid tumors [23, 24]. The current study aims to assess the clinical role of two long noncoding RNAs: long intergenic non-protein coding RNA 641 (lncRNA-641) and long intergenic non-protein coding RNA 565 (lncRNA-565) as minimal invasive molecular markers for GBM and detect their role as prognostic liquid biomarkers.

Patients and methods

The study was conducted on patients presented to Clinical Oncology Department, Faculty of Medicine, Ain Shams University from September 2019 to October 2021. After obtaining the approval from the Ethical Committee and individuals or their first degree relatives or legal guardians signed the informed consents.

Enrolled individuals

Blood samples were collected from newly diagnosed adult glioblastoma (GBM) patients (n = 35) whom fulfill the following inclusion criteria: newly diagnosed GBM cancer patients with no history of other malignancy, age more than 18 years, with performance less than or equal 2, according to the ECOG (the Eastern Cooperative Oncology Group) [25] and samples were withdrawn before they have received any oncological treatment strategies. Any GBM patients whom did not fulfill the inclusion criteria were excluded from the study. As a control group, 15 healthy individuals were enrolled in the study; both groups were of matched ages.

Sample collection and processing

Three ml of blood samples were collected from all individuals in gel vacutainer tubes (Greiner Bio-One GmbH, Kremsmünster, Austria) and transferred to lab within 30 min.
for IncRNAs detection. After centrifugation of blood samples at 10,000×g for 10 min at 4 °C (3-18KS, Sigma, Germany) the sera were separated and stored into aliquots and stored immediately in RNase free tubes at –80 °C till further processing.

IncRNA extraction

IncRNA extraction was performed using miRNeasy Mini kit (Catalogue # 217004, Qiagen, USA). Briefly, 5 vol QIAzol lysis reagent (RNA extraction reagent) were added to a volume of the thawed serum sample, and then vortexed was applied. Lysates were left for 5 min at room temperature (25 °C) to promote dissociation of nucleo-protein complexes. Phase separation step was executed by adding chloroform in a ratio of 1:1 volume of starting sample to the starting sample to the tube containing the lysate, and vortex was applied followed by centrifugation at 12,000×g for 15 min (4 °C). The upper aqueous phase was transferred to a new collection tube. Afterwards, 1.5 vol of 100% ethanol were added to the aqueous phase followed by pipetting up and down several times. The sample (up to 700 μl) was transferred into an RNeasy Mini spin column in a 2 ml collection tube and then centrifuged for 15 s at ≥ 8000×g for 15 min at room temperature. The RWT buffer (700 μl) was added to the RNeasy Mini spin column. After centrifugation, the flow-through was discarded and RPE buffer (500 μl) was added and the column was centrifuged and flow-through was discarded. The RPE step was repeated. The RNeasy Mini spin column was placed into a new 2 ml collection tube and centrifuged at full speed (14,000×g) for 2 min. Finally, the spin column was placed into a new 2 ml collection tube and added and the column was centrifuged and flow-through was discarded and RPE buffer (500 μl) was added to the RNeasy Mini spin column. After centrifugation, 15 min at room temperature. The RWT buffer (700 μl) was transferred into an RNeasy Mini spin column in a 2 ml collection tube. RNase-free water (30 μl) was directly added onto the RNeasy Mini spin column membrane and centrifugation was done for 1 min at ≥ 8000×g. The purity and the concentration of the purified IncRNA was detected using spectrophotometer Nano-drop (Quawell, Q-500, Scribner, USA) and stored at –80 °C till further assessments.

Reverse transcription and cDNA preparation

Reverse transcription of IncRNA was carried out using RT² First Strand Kit (Cat number # 330404, Qiagen, USA) as recommended in the manufacturer’s instructions by using a total volume of 10 μl of reverse transcription reaction components. The polymerase chain reaction (PCR) tubes were then placed in thermal cycler (SureCycler 8800, Agilent, USA) and the transcription profile was adjusted for 60 min at 37 °C. Complementary DNA purity and concentration was detected using spectrophotometer Nano-drop (Quawell, Q-500, Scribner, USA) and stored at –20 °C till performing qPCR.

Quantitative real-time PCR (qPCR)

Quantitative real-time PCR was performed using miScript primer assay (Cat number 330701, Qiagen, USA) for IncR 565 (Accession no. LPH23084A), and for IncR 641 (Accession no. LPH21254A) the reaction was carried out using RT² qPCR SYBR Green (Cat number 330520, Qiagen, USA). Their expression was normalized using β-Actin (Accession no. LPH28471A) as a housekeeping gene. The reactions for IncRNA primer assays were carried out by using cDNA with concentrations adjusted to 2 ng/PCR reaction, and a total volume of 25 μl, whereas cycling conditions were: heating step at 95 °C for 10 min where HotStart DNA Taq-polymerase was activated, followed by 40 cycles for denaturation at 95 °C for 15 s, then annealing at 55 °C for 40 s. Extension was then performed at 72 °C for 30 s, in which fluorescence was acquired and detected by Stratagene Real-time PCR system (Max3005P QPCR system, Stratagene, Agilent biotechnology, USA). The relative expression levels of the investigated IncRNAs were evaluated using the 2−ΔΔCt method. The cycle threshold (Ct) value is the number of qPCR cycles required for the fluorescent signal to cross a specified value. The relative expression levels of the investigated IncRNAs were evaluated using the 2−ΔΔCt method [26]. ΔCt was calculated by subtracting the Ct values of β-Actin from Ct of investigated IncRNA for detection of its expression, then ΔΔCt was calculated by subtracting the ΔCt of the control samples from the ΔCt of the GBM samples, after words 2−ΔΔCt (fold change expression) was calculated for IncRNAs under investigation.

Treatment strategy

All GBM patients were assessed clinically (by complete history, clinical examination and neurologic examination) and with brain imaging in order to receive their standardized treatment protocol, which involve maximum safe resection (if possible), followed by radiotherapy conventional fractions (total dose of 60 Gy, given 2 Gy per fraction for 30 fractions over 6 weeks) or hypofractionation (45 Gy in 15 fractions over 3 weeks) with concomitant temozolomide (TMZ) chemotherapy (75 mg/m² every day till end of radiotherapy) with regular follow up, then re-evaluated clinically and radiologically followed by adjuvant six cycles of TMZ treatment at a dose of 150 mg/m² body surface area from days 1 to 5 every 28 days with clinical monitoring.

During regular clinical follow up, patient were assessed by gadolinium-enhanced magnetic resonance imaging (Gd-MRI) 45 days after RT and then performed every 3 months or at time of clinical evidences of neurologic progression. Tumor response was evaluated on the basis of radiological RANO response criteria (2010) [27]. Complete response (CR): disappearance of all known brain lesion. Partial
response (PR): 50% or greater decrease in measurable brain lesion or an objective improvement in evaluable brain lesion. Stable disease (SD): brain lesion unchanged (<50% decrease or <25% increase in the size of measurable lesions). Progressive disease (PD): ≥ 25% increase in size of some or all of brain lesions and/or the appearance of any new brain lesions. Another risk factor was steroid dependency: it is defined as failure to taper steroids after radiotherapy course or increasing the dose. It indicates bad prognosis in GBM patients.

Statistical analysis

Data was analyzed using SPSS (version 12 SPSS, Inc., Chicago USA) and P-value were two-tailed and considered significant if <0.05. The fold change in investigated lncRNAs was calculated using the equation of $2^{-\Delta\Delta Ct}$. The association between the clinico-pathological and demographic factors with investigated lncRNAs was determined by ANOVA analysis. Receiver operating characteristic (ROC) curve was plotted between GBM patients as positive and healthy individuals as negative to detect the sensitivities and the specificities for the lncRNAs and their clinical efficacy [28]. Progression free survival (PFS): it’s time from start of enrollment till progression of the disease proved by MRI imaging or clinical deterioration. Overall survival (OS): was calculated from the date of random assignment to the date of death or lost follow up, both were analyzed using Kaplan–Meier statistical method and compared by log-rank test.

Results

The studied cohorts were divided into two groups: newly diagnosed GBM patients (n = 35) with an age range (22–62), 26 of them (74.3%) were below 60 years with a mean age of (47.7 ± 1.2 years), 24 of them (68.6%) were males; the second group was healthy individuals serve as control group (n = 15) with an age range (22–58), with a mean age (33.9 ± 8.1 years), 9 of them (60%) were males. According to the performance status, 16 patients had (ECOG < 2), while other patients had (ECOG = 2). Medical comorbidities reported as 6 diabetic, 4 hypertensive, 3 viral hepatitis (HCV) patients and 5 with other medical comorbidities (asthma, hypothyroidism). Positive family history of GBM was reported in 3 patients. The estimated mean expression of lncR 565 for GBM patients group [mean ± standard error of

Tumor size was initially ≥ 5 cm in 22 patients. Diagnosis of GBM was pathologically confirmed in 27 cases [after biopsy (N = 17) or surgical resection (N = 10)], while MRS was used in diagnosis of 8 cases with non-accessible sites. Clinico-pathological characteristics for GBM cases were summarized in Table 1. The estimated mean expression of lncR 565 for GBM patients group [mean ± standard error of

### Table 1 Clinico-pathological characteristics of GBM patients (N = 35)

| Character                        | N, (%)   |
|---------------------------------|----------|
| Comorbidities                   |          |
| DM                              | 6, (17.1%) |
| HTN                             | 4, (11.4%) |
| Viral hepatitis                 | 3, (8.6%)  |
| Others                          | 5, (14.3%) |
| Irrelevant                      | 18, (51.4%) |
| Family history                  |          |
| GBM                             | 3, (8.6%)  |
| Other tumors                    | 5, (14.3%) |
| ECOG                            |          |
| < 2                             | 16, (45.7%) |
| ≥ 2                             | 19, (54.3%) |
| Presenting symptoms             |          |
| ICT                             | 23, (65.7%) |
| Neurological deficient          | 12, (34.3%) |
| Convulsions                     | 13, (37.1%) |
| Tumor site                      |          |
| Rt site                         | 17, (48.6%) |
| Lt site                         | 22, (62.9%) |
| Multiplicity                    | 5, (14.3%) (4 Bilateral and 1 unilaterial) |
| Site of primary lesion          |          |
| Frontal                         | 7, (20%)  |
| Non-frontal (temporo-parietal and posterior fossa) | 26, (74.3%) |
| Both (frontal and non-frontal)  | 2, (5.7%)  |
| Tumor size                      |          |
| < 5 cm                          | 13, (37.1%) |
| ≥ 5 cm                          | 22, (62.9%) |
| Diagnosis                       |          |
| MRS                             | 8, (22.9%) |
| Pathology (intervention)        | 27, (77.1%) |
| Type of intervention            |          |
| Biopsy                          | 17, (63%) |
| Resection                       | 10, (37%) |
| a Gross total resection         | 4, (40%)  |
| b Subtotal resection            | 6, (60%)  |

DM diabetes mellitus, HTN hypertension, MF medically free, FM family history, ECGO performance status, ICT increased intracranial tension, Rt right, Lt left, MRS magnetic resonance spectroscopy
mean, SEM = 106 ± 28.3) and (9.2 ± 1.6) for control group. While lncR 641 mean expression was (89 ± 20) for GBM group and (8.1 ± 1.8) for control group. That showed statistically significant differences between GBM group and control group (at P value = 0.031, and 0.021) for lncR 565 and lncR 641 levels, respectively, as shown in Fig. 1A, B. Their diagnostic efficacy as were determined by plotting ROC curve (Fig. 1C). Accordingly, significant difference was reported between GBM and control. Moreover, the diagnostic efficacy (sensitivity and specificity) revealed 97% and 100% for lncR 565 at AUC equals 0.994 with a cutoff point 19.18 and 100%, 93.3% for lncR 641 with AUC equals 0.995 with a cutoff point 16.16.

Using non-parametric analysis by Mann–Whitney and Kruskal–Wallis Test the expression levels of investigated lncRNAs with clinical criteria for enrolled GBM cases were detected. The impact of lncR 565 and lncR 641 on demographic characteristics reported no significant difference between age, gender, family history but statistically significant higher mean levels were reported with performance status equals 2 (P= 0.04 and 0.03, respectively), presentation with fits was associated with significantly lower mean level (P= 0.001 and 0.02, respectively). A part from lncR 641, significantly higher mean lncR 565 level was reported in patients presented with increased intracranial tension (P= 0.002) and tumor size > 5 cm (P= 0.04).

Upon treatment, as summarized Table 2, 32 cases received radiotherapy (CCRTH). Conventional fractions were used for treatment of 18 cases, while the remaining received hypo-fractionated radiotherapy. Conformal (3D) technique of radiotherapy was used in 23 cases, while IMRT was used in 9 cases. Subsequently, 21 patients received adjuvant chemotherapy. As regards toxicity, it was tolerable and manageable; radiotherapy toxicity (neurocognitive symptoms, dermatitis, alopecia, otitis media) was reported as acute toxicity (≥ G3) in 12 cases and late in 3 cases. While for chemotherapy toxicity, 11 patients reported G1 and G2 (most commonly of GIT symptoms) and G3 toxicity (hematological) only in 1 patient. The estimated lncR 565 and -641 expression mean levels in radiotherapy treated patients

![Fig. 1 A Box plot comparing lncRNA565 expression level in control group versus GBM, B box plot comparing lncRNA641 expression level in control group versus GBM, and C receiver operating characteristic curve (ROC curve) for investigated lncRNAs. Arrows donate to the optimal cutoff point that discriminates between GBM cases and control individuals](image-url)
were (mean rank = 110.7, and 88.84, respectively). Significantly higher levels of lncR 641 were associated with steroid dependence (N = 22) and (P = 0.011).

According to treatment response, patients were categorized into CR (2), PR (5), SD (11) and disease progression (PD = 14), but they did not show significant correlation with investigated lncRNAs.

Survival analyses showed that after median follow up of (10 months) for 32 GBM patients, the estimated median PFS was 11 months and median OS was 13 months, 3 lost follow up (1 COVID related death during radiotherapy planning and 2 others were lost follow up on first week of radiotherapy), they were excluded from treatment and survival analysis.

After follow up, mean rank levels for lncRNAs expression reported significant higher levels in relation to progressed cases as shown in Fig. 2A, B and death as shown in Fig. 2C, D.

The mean levels of lncRNAs in GBM patients were 97 for lncR 565, and 89 for lncR 641. Accordingly, the expression level for lncRNAs were grouped into high (above the mean value) and low (below or equal the mean value). Kaplan–Meier curves were used to detect the relation between investigated lncRNAs and survival pattern.

Significant difference was reported between lncR 565 and lncR 641 with PFS. GBM patients with high expression levels reported worse PFS (P = 0.002 and 0.001, respectively) as shown in Fig. 3A, B when compared to their counterparts with low expression levels. Similarly, expression of lncR 565 and lncR 641 reported significant differences with OS, where GBM patients with worse OS showed significantly higher expression levels (P = 0.003 and 0.002, respectively), as presented in Fig. 3C, D. Notably, patients underwent gross total resection (N = 4) showed longer PFS (24, 24, 22, 20 months, respectively) and OS (25, 24, 24, 20 months, respectively).

Both lncRNA were significantly correlated with each other when all individuals (n = 50) were considered (X² = 0.825, P < 0.0001) and when GBM cases (n = 35) where considered (X² = 0.805, P < 0.0001).

### Discussion

Growing evidence designates the association between dysregulation of lncRNAs expression with various types of cancer [19, 29], including GBM [30]. Moreover their accessibility to be detected in liquid samples made them of great value for diagnosis, prediction of prognosis and follow-up molecular [31]. In previous studies it has been reported that biological and physiological roles of lncRNAs have been investigated under limelight that their expression takes part in many biological processes and their aberrant expression is confirmed in gliomas. The recent researches on lncRNAs have reported that intergenic nc-RNA can act as endogenous miRNA sponge in cancer cells to promote tumor development [32]. Hence molecular classification based on expression of lncRNAs may direct for gene therapy and may aid to a better procedure for targeted therapy selection [33, 34].

In the current prospective study, two lncRNAs were investigated (lncR 565 and lncR 641) in blood samples from GBM patients and a healthy control group were recruited. lncR 565 reported significant increase in GBM cases and can be utilized as liquid molecular marker for diagnosis of GBM. Similarly, lncR 641 reported significant increase in GBM cases as compared to control ones with diagnostic efficacy.

| Received treatment | N (%) | 2−ΔΔCt lncRNA-565 | 2−ΔΔCt lncRNA-641 |
|--------------------|-------|-------------------|-------------------|
| CCRTH (TEMODAL)    | No    | 3 (8.57%)         | 18.6              |
|                    | Yes   | 32 (91.42%)       | 17.7              |
| RTH fractions      | Conventional | 18 (56.25%)       | 16.8              |
|                    | Hypofractionated | 14 (43.75%)       | 17.9              |
| Rth technique      | 3D conformal | 23 (71.87%)       | 12                |
|                    | IMRT  | 9 (28.12%)        | 24.5              |
|                    |       | (P = 0.003)       | 24                |
| Adjuvant CTH       | No    | 11 (34.37%)       | 18.6              |
|                    | Yes   | 21 (65.62%)       | 16.5              |
| Steroid dependence | No    | 10 (31.25%)       | 12.3              |
|                    | Yes   | 22 (68.75%)       | 18.41             |

### Table 2

Expression level of lncRNA565 and lncRNA641 in GBM patients in relation to received treatment

CCRTH concurrent chemo-radiotherapy, CTH chemotherapy, RTH radiotherapy

 Springer
of absolute sensitivity and 93.3% specificity. These findings indicate the usefulness of lncRNA641 as liquid molecular marker that can aid in diagnosis of GBM.

Alterations of lncR 565 and lncR 641 in GBM have been rarely investigated. Both were part of a recent risk scoring model using lncRNAs in GBM patients was constructed to divide them into different risk groups with significantly different survival rates. In addition, the study pointed that both lncRNAs showed predictive value for patient’s survival. Aberrant altered levels of lncR 565 and lncR 641 have been linked to ECM receptor interaction, focal adhesion and MAPK signaling pathways [20], that is involved in controlling GBM cell proliferation and migration [35].

Regarding to the current study, the relation between expression levels of both lncRNAs (lncR 565 and lncR 641) and the clinical data of studied cases, their levels reported significant change with worse performance status (= 2), also lncR 565 mean level was significantly increased with patients reporting tumor mass ≥ 5 cm indicating that both lncRNAs may be linked to tumor aggressiveness. Although it has been reported earlier that GBM is an age-related neurological disorder in adults [2], current data did not report significant difference between investigated lncRNAs and age of GBM cases.

Given the sizable studies of the role for lncRNAs cellular processes [34, 36] made them important to be considered in the context of GBM heterogeneity and treatment resistance. In the current study the median follow-up for GBM patients was 10 months and the estimated median PFS was 11 months and median OS was 13 months which concurrent with the median follow up period of previous studies on GBM [37, 38]. Survival pattern analysis showed higher levels of lncR 565 and lncR 641 reported significant relation to worse PFS and OS. These findings revealed the impact role of lncRNAs as minimally non-invasive liquid biopsy marker to be used as predictor for prognosis. The current finding is consistent with reported data from Liang and his colleagues who confirmed that lncR 565 and lncR

Fig. 2 Distribution of lncRNAs versus follow-up pattern (median follow up 10 months). Progression free survival among GBM cases as 9 cases reported free survival and 26 GBM were progressed for (A) lncRNA565 and (B) lncRNA641. Overall survival pattern among GBM cases as 14 GBM cases survived and 18 GBM were died for C lncRNA565 and D lncRNA641.
641 reported prognostic signature for GBM cases using several bioinformatics approaches [19].

In conclusion, to our knowledge this is the first study to detect IncR 565 and IncR 641 in liquid biopsy samples from Egyptian GBM patients although with some limitation due to small number of sample but it gives a shed on the importance of the clinical impact of these investigated IncRNAs as both diagnostic and prognostic markers which may aid in the future for RNA-based therapeutics.

Acknowledgements The instruments listed in the current study were purchased through a Grant from Science, Technology & Innovation Funding Authority (STDF) through Capacity Building Grant Fund (CBG, No. 4940).

Author contributions Study conception and design: MS, LRE, DAE, ASS, NBE and RGA. Provision of samples and clinical follow-up: LRE, DAE, ASS, NBE and RGA. Acquisition of data: RGA. Analysis and interpretation of data: MS, LRE and RGA. Drafting of manuscript: MS, LRE, DAE, ASS, NBE and RGA. Critical revision: MS, LRE, DAE, ASS, NBE and RGA.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). Authors declare that there is no funding agent for the work.

Data availability Author elects not share data.

Declarations

Conflict of interest Authors report no conflicts of interest in this work.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source.
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Perrin SL, Samuel MS, Koszyca B et al (2019) Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochem Soc Trans 47(2):625–638
2. Kim M, Ladomerys E, Mozny A et al (2021) Glioblastoma as an age-related neurological disorder in adults. Neurooncol Adv 3(1):vda0125
3. Abd El Moumen MS, Ezz El Arab LR, Mosalam N et al (2019) Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: a single-center experience in the Middle East region. Clin Neurol Neurosurg 182:92–97
4. Ayoub Z, Gears F, Najjar M et al (2019) Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: a single-center experience in the Middle East region. Clin Neurol Neurosurg 182:92–97
5. Kassem NM, Kassem HA, Selim H et al (2022) Targeted next generation sequencing provides insights for the genetic alterations in liquid biopsy of Egyptian brain tumor patients. Egypt J Med Genet 23(1):1–8
6. Haniel F, Muzaffar K, Perveen K et al (2017) Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3
7. Von Rosenstiel C, Wiestler B, Haller B et al (2020) Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method. J Clin Pathol 73(2):112–115
8. Louis DN, Perry A, von Reifenberger GDA, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuro-pathol 131:803–820
9. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neurooncology 23(8):1231–1251
10. Vecera M, Sana J, Lipina R et al (2018) Long non-coding RNAs in gliomas: from molecular pathology to diagnostic biomarkers and therapeutic targets. Int J Mol Sci 19(9):2754
11. Wang Y, Chen J, Cowan DB et al (2021) Non-coding RNAs in cardiac regeneration: mechanism of action and therapeutic potential. Semin Cell Dev Biol 118:150–162
12. Stockhouse CT, Gillespie GD, Willey CD (2020) Exploring the roles of IncRNAs in GBM pathophysiology and their therapeutic potential. Cells 9(11):2369
13. Kamel MM, Matboli M, Sallam M et al (2016) Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma. Transl Res 168:134–145
14. Li J, Meng H, Bai Y et al (2016) Regulation of IncRNA and its role in cancer metastasis. Oncol Res 23(5):205
15. Bonner ER, Bornhorst M, Packer RJ et al (2018) Liquid biopsy for pediatric central nervous system tumors. NPJ Precis Oncol 2(1):1–9
16. Li Z, Hong S, Liu Z (2018) IncRNA LINCC00641 predicts prognosis and inhibits bladder cancer progression through miR-197 3p/ KLF10/PTEN/P13K/AKT cascade. Biochem Biophys Res Commun 503(3):1825–1829
17. Li Y, Zhao L, Zhao P et al (2019) Long non-coding RNA LINCC00641 suppresses non-small-cell lung cancer by sponging miR-424-5p to upregulate PLSCR4. Cancer Biomark 26(1):79–91
18. Gong M, Luo C, Meng H et al (2019) Upregulated LINCC00565 accelerates ovarian cancer progression by targeting GAS6. Onco Targets Ther 12:10011
19. Liang R, Zhi Y, Zheng G et al (2019) Analysis of long non-coding RNAs in glioblastoma for prognosis prediction using weighted gene co-expression network analysis, Cox regression, and L1-LASSO penalization. OncoTargets Ther 12:157
20. Zhang XQ, Sun S, Lam KP et al (2013) Long non-coding RNA signature in glioblastoma multiforme predicts survival. Neurobiol Dis 58:123–131
21. Swellam M, Ezz El Arab L, Al-Postany AS et al (2019) Clinical impact of circulating oncogenic MiRNA-221 and MiRNA-222 in glioblastoma multiform. J Neurooncol 144(3):545–551
22. Labib EM, Ezz El Arab LR, Ghanem HM et al (2020) Relevance of circulating miRNA-21 and MiRNA-181 in prediction of glioblastoma multiforme prognosis. Arch Physiol Biochem. https://doi.org/10.1080/13813455.2020.1739716
23. Li D, Du L, Chen D et al (2016) Reduced CD146 expression promotes tumorgenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling. Oncotarget 7(26):40704
24. Swellam M, Hekmat ME, Shawki MA et al (2021) Clinical impact of LncRNA XIST and LncRNA NEAT1 for diagnosis of high-risk group breast cancer patients. Curr Probl Cancer 45(5):100709
25. Oken MM, Creech RH, Torrey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–656
26. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25(4):402–408
27. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-oncology Working Group. J Clin Oncol 28(11):1963–1972
28. Zweig MH, Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39(4):561–577
29. Swellam M, Bakr NM, El Magdoub HM et al (2021) Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis. J Mol Neurosci 71(4):836–844
30. Rezaei O, Tamizkar KH, Shariﬁ G et al (2021) Emerging role of long non-coding RNAs in the pathobiology of glioblastoma. Front Oncol 10:3381
31. Momtazmanesh S, Rezaei N (2021) Long non-coding RNAs in diagnosis, treatment, prognosis, and progression of glioma: a state-of-the-art review. Front Oncol 11:712786
32. Yadav B, Pal S, Rubstov Y et al (2021) LncRNAs associated with glioblastoma: from transcriptional noise to novel regulators with a promising role in therapeutics. Mol Ther Nucleic Acids 24:728–742
33. Li J, Zhang Q, Ge P et al (2020) FAM225B is a prognostic IncRNA for patients with recurrent glioblastoma. Dis Mark 2020:888085
34. Mahinfar P, Baradaran B, Davoudian S et al (2021) Long non-coding RNAs in multidrug resistance of glioblastoma. Genes 12(3):455
35. Mao H, LeBrun DG, Yang J et al (2012) Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Investig 30(1):48–56
36. DeSouza PA, Qu X, Chen H et al (2021) Long, noncoding RNA dysregulation in glioblastoma. Cancers 13(7):1604
37. Efremov L, Abera SF, Bedir A et al (2021) Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German cancer registries. J Cancer Res Clin Oncol 147(11):3381–3390
38. Maire A, Maklad AM, Altwairqi A et al (2021) Treatment patterns and outcomes among elderly glioblastoma patients at KFMC, Riyadh. OncoTargets Ther 15:135–144

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.